Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Stealth Biotherapeutics Corp Ads (MITO)

Stealth Biotherapeutics Corp Ads (MITO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 86,763
  • Shares Outstanding, K 55,617
  • Annual Sales, $ 0 K
  • Annual Income, $ -57,460 K
  • 60-Month Beta 2.03
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade MITO with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/21
See More
  • Average Estimate -0.02
  • Number of Estimates 1
  • High Estimate -0.02
  • Low Estimate -0.02
  • Prior Year -0.02
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.1500 +35.65%
on 05/17/21
2.1000 -25.71%
on 06/02/21
+0.3800 (+32.20%)
since 05/14/21
3-Month
1.0600 +47.17%
on 04/21/21
2.4500 -36.33%
on 05/06/21
-0.2500 (-13.81%)
since 03/16/21
52-Week
1.0600 +47.17%
on 04/21/21
2.5800 -39.53%
on 02/09/21
-0.4126 (-20.92%)
since 06/16/20

Most Recent Stories

More News
Thinking about buying stock in Stealth BioTherapeutics, BlackBerry, Ideanomics, Seelos Therapeutics, or Altimmune?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MITO, BB, IDEX, SEEL, and ALT.

ALT : 16.46 (+16.49%)
IDEX : 3.05 (+5.54%)
MITO : 1.5600 (unch)
SEEL : 3.20 (+2.89%)
BB : 12.88 (-7.93%)
Stealth BioTherapeutics Receives Orphan Drug Designation from the European Medicines Agency for Elamipretide for the Treatment of Barth Syndrome

, /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for diseases involving...

MITO : 1.5600 (unch)
Stealth BioTherapeutics to Present at Jefferies Virtual Healthcare Conference

, /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving...

MITO : 1.5600 (unch)
Thinking about buying stock in Stealth BioTherapeutics, AMC Entertainment, XpresSpa, Western Copper and Gold, or Dolphin Entertainment?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MITO, AMC, XSPA, WRN, and DLPN.

AC : 37.89 (-0.63%)
WRN : 2.19 (-2.67%)
DLPN : 8.87 (+2.66%)
MITO : 1.5600 (unch)
XSPA : 1.5600 (+1.30%)
AMC : 55.18 (-6.54%)
Stealth BioTherapeutics Reports First Quarter 2021 Financial Results And Recent Business Highlights

, /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq:MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for diseases involving...

MITO : 1.5600 (unch)
Stealth BioTherapeutics Announces Additional Development Financing to Advance Elamipretide Clinical Trials

, /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for diseases involving...

MITO : 1.5600 (unch)
Stealth BioTherapeutics Announces Poster Presentation at American College of Cardiology (ACC) Annual Meeting

, /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for diseases involving...

MITO : 1.5600 (unch)
Stealth BioTherapeutics to Present at Upcoming Investor Conferences in May

, /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving...

MITO : 1.5600 (unch)
Stealth BioTherapeutics to Report First Quarter Financial Results on Tuesday, May 18, 2021

, /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving...

MITO : 1.5600 (unch)
Thinking about buying stock in Stealth BioTherapeutics, Rocket Comp, Cocrystal Pharma, AMC Entertainment, or Nokia?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MITO, RKT, COCP, AMC, and NOK.

AC : 37.89 (-0.63%)
COCP : 1.3000 (+0.78%)
MITO : 1.5600 (unch)
AMC : 55.18 (-6.54%)
NOK : 5.22 (-1.32%)
RKT : 19.69 (-2.81%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Stealth BioTherapeutics Corp is a biopharmaceutical company. It is engaged in developing therapies to treat the mitochondrial dysfunction associated with genetic mitochondrial diseases and many common age-related diseases. The company's product pipeline includes Elamipretide, SBT-20 and SBT-272 which...

See More

Key Turning Points

3rd Resistance Point 1.6733
2nd Resistance Point 1.6267
1st Resistance Point 1.5933
Last Price 1.5600
1st Support Level 1.5133
2nd Support Level 1.4667
3rd Support Level 1.4333

See More

52-Week High 2.5800
Fibonacci 61.8% 1.9994
Fibonacci 50% 1.8200
Fibonacci 38.2% 1.6406
Last Price 1.5600
52-Week Low 1.0600

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar